For example, ibrutinib, which had high predicted sensitivity for all the BRCA samples, has been investigated for its impact on human epidermal growth factor receptor 2 (HER2)–amplified breast cancers.56 Similarly, lapatinib, in combination with trastuzumab, has recently been tested clinically for HER2-amplified metastatic colorectal cancer.57 This evidence concerns the gene ERBB2 and breast cancer.